Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
翰思艾泰生物醫藥科技(武漢)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3378)

VOLUNTARY ANNOUNCEMENT
NOTICE ON VOLUNTARY EXTENSION OF LOCK-UP PERIOD BY SHAREHOLDERS

This announcement is made by the board (the "**Board**") of directors (the "**Directors**") of Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (the "**Company**" or "**Hanx Biopharmaceuticals**") on a voluntary basis.

References are made to the prospectus of the Company dated December 15, 2025 and the announcement of allotment results of the Company dated December 22, 2025, in relation to, among other things, the lock-up restrictions applicable to the shares held by all pre-IPO shareholders (including the controlling shareholder of the Company) and the cornerstone investors. The lock-up period for the controlling shareholder and the pre-IPO investors will expire on December 22, 2026, and the lock-up period for the cornerstone investors will expire on June 22, 2026.

Recently, the Company received a notice from all controlling shareholders, pursuant to which the controlling shareholders have undertaken that they will not reduce any of their respective shareholdings in the Company in any manner during the extended lock-up period of 12 months from the expiry date of the original lock-up period.

In addition, the Company has received notifications from certain pre-IPO shareholders and cornerstone investors, pursuant to which certain pre-IPO shareholders have undertaken that they will not reduce their respective shareholdings in the Company in any manner during the extended lock-up period of 6 months from the expiry date of the original lock-up period; and certain cornerstone investors have undertaken that they will not reduce their respective shareholdings in the Company in any manner during the extended lock-up period of 7 months from the expiry date of the original lock-up period.

The Company believes that the Lock-up Period Extension demonstrates the full confidence of the aforesaid shareholders in the future prospects, core technical strengths and long-term value of the Company. The aforesaid shareholders will also continuously review the Company's performance and may consider further extending the lock-up period based on the Company's business development.

Details of the specific shareholding information and the extended lock-up arrangements of the aforesaid shareholders are as follows:

I) Cai Zhang Biotechnology (Hangzhou) Co., Ltd. (蔡張生物科技(杭州)有限責任公司) (holding 55,300,000 shares), Wuhan Hanx Tai Management Consulting Partnership (Limited Partnership) (武漢市翰思泰管理諮詢合夥企業(有限合夥)) (holding 3,045,070 shares) and Hanx Biopharmaceuticals (HK) Limited (翰思生物醫藥(香港)有限公司) (holding 17,793,640 shares) have each undertaken that they will not reduce their respective shareholdings in the Company in any manner from the expiry date of the original lock-up period to December 22, 2027 (inclusive);

II) Beijing Lapam Biopharmaceutical Venture Capital Center (Limited Partnership) (北京龍磐生物醫藥創業投資中心(有限合夥)) (holding 12,860,470 shares), Betta Pharmaceuticals Co., Ltd. (貝達藥業股份有限公司) (holding 6,430,230 shares), Hangzhou Taikun Equity Investment Fund Partnership (Limited Partnership) (杭州泰鯤股權投資基金合夥企業(有限合夥)) (holding 2,562,050 shares), Tibet Longpan Small and Medium Enterprise Development Fund Equity Investment Partnership (Limited Partnership) (西藏龍磐中小企業發展基金股權投資合夥企業(有限合夥)) (holding 1,195,620 shares), Hainan Yangtze Investment Co., Ltd. (海南揚子投資有限公司) (holding 1,024,080 shares), Yangtze Investment(HK)Limited (holding 779,940 shares), and Lapam Capital HK Co., Limited (holding 596,040 shares) have each undertaken that they will not reduce their respective shareholdings in the Company in any manner from the expiry date of the original lock-up period to June 22, 2027 (inclusive);

III) Awaken Thunder Capital Limited (春雷資本有限公司) (holding 125,000 shares) has undertaken that it will not reduce its shareholdings in the Company in any manner from the expiry date of the original lock-up period to January 22, 2027 (inclusive);

IV) The ultimate client of Guotai Junan Investments (Hong Kong) Limited (國泰君安證券投資(香港)有限公司) (directly holding 343,700 shares) (Kunyang) (i.e. Kunyang New Pattern No.1 Private Securities Investment Fund (鯤洋新格局1號私募證券投資基金)), has undertaken that it will not reduce its shareholdings in the Company in any manner from the expiry date of the original lock-up period to January 22, 2027 (inclusive).

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Dr. ZHANG Faming
Chairman and Executive Director

Hong Kong, June 24, 2026

As at the date of this announcement, the Company's Board comprises (i) Dr. Zhang Faming, Dr. Henry Qixiang Li, Ms. Xiao Jieyu and Mr. Liu Min as executive Directors; (ii) Dr. Li Jian as a non-executive Director; and (iii) Dr. Bi Honggang, Mr. Chen Qifeng, Mr. Wong Sai Hung and Dr. Zhang Qiongguang as independent non-executive Directors.